Sheryl Merkin, M.S., F.N.P., C.D.E., Sharon Movsas, M.S., R.D., C.D.E., and Joel Zonszein, M.D., C.D.E.
Dr. Zonszein is Professor of Clinical Medicine, Albert Einstein College of Medicine. All authors are staff members of the Clinical Diabetes Center of Montefiore Medical Center, New York.
Within the past 12 months, Dr. Zonszein has been on the Speakers Bureau of Merck, Sanofi Aventis, Takeda Pharmaceuticals, Eli Lilly & Co. and Novo Nordisk; Ms. Merkin has been on the Speakers Bureau of Sanofi Aventis and Novo Nordisk; Ms. Movsas reports no commercial conflicts of interest.
Estimated course time: 1 hour(s).
Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Upon completion of this Cyberounds®, you should be able to:
Describe the new classification of diabetes
Discuss the pathogenesis of Type 1 diabetes
Identify individuals with Type 1 diabetes using clinical and laboratory parameters.
